Gelesis announced today that it partnered with China Medical Systems for the commercialization of the Plenity weight loss pill in China. Under the terms of the deal, CMS will provide $35 million upfront via licensing fees and equity investment, plus there remains the potential for an additional $388 million in future milestone payments, as well […]
Gelesis said today that it received a $10.6 million (EU €9.4 million) grant to support the manufacturing of its Plenity weight loss device. The Boston-based company said it received the grant from the Puglia Region of Italy, where its material science R&D and clinical supply manufacturing is located. Funds from the grant came from the […]
Gelesis (Boston) recently announced that it has received FDA clearance for its Plenity weight management prescription drug. The drug is a weight management aid for adults who have a body mass index of 25-40 kg/m2 and is supposed to be used with diet and exercise. It can be used in people with and without […]
PureTech subsidiary Gelesis today touted results from a pivotal weight-loss study of its obesity drug, Gelesis100. The study met one of its two primary endpoints, with 58% of adults in the treatment arm experiencing clinically-meaningful weight loss of 5% or more. Get the full story at our sister site, Drug Delivery Business News.
Stryker, Monsanto director Parfet steps down Stryker (NYSE:SYK) and Monsanto (NYSE:MON) said this week that board member William Parfet stepped down from their boards, but declined to reveal the reason behind the abrupt departures. Parfet, who joined Stryker’s board in 1993 and was a director at the agribusiness giant for 16 years, stepped down effective […]
A day after officially spiking its plans for an initial public offering, Gelesis said it raised another $31.5 million for its anti-obesity pill. The Gelesis100 is designed to induce a feeling of satiety and improve glycemic control, using a super-absorbent hydrogelthat expands in the stomach after being swallowed. Boston-based Gelesis tabled the $56 million IPO in May […]
Gelesis reportedly tabled its pending, $56 million initial public offering due to the turbulence of the U.S. biotech market.
The Boston-based company said in April that would look to float 4 million shares at $12 to $14 apiece. Gelesis makes makes an anti-obesity pill using a super-absorbent hydrogel to induce feelings of satiety.
Gelesis just last week drummed up a $22 million funding round, but that’s not stopping the Boston-based company from registering for an initial public offering worth $60 million.
Damned if you do, damned if you don’t. That’s the predicament many providers find themselves in with the two current CMS e-prescription initiatives.
Medicare legislation passed in the Medicare Improvements for Patients and Providers Act of 2008 authorized the Centers for Medicare and Medicaid Services to offer incentives for meeting e-prescribing requirements, but providers who meet the standards for those rewards may still be penalized if they do not meet the threshold of sending at least 10 ePrescriptions between January 1 and June 30 of 2011.
Curbing obesity may be as simple as popping a pill before meals.
A new capsule called Attiva does just that — expanding in the stomach to significantly reduce hunger between meals and make people feel fuller, according to the results of a clinical trial released by Boston-based Gelesis Inc.